Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine  |  Integrative & Functional Medicine Physician

Why Strain Identity Matters Before Anything Else

In MCAS clinical practice, one of the most common questions I receive is whether a particular probiotic is “safe.” The honest answer is that the question itself is incomplete. The genus Lactobacillus — now reclassified into 25 separate genera following 2020 nomenclature changes — contains strains that span the full clinical spectrum: some downregulate mast-cell receptors, some are histamine-neutral, and some are histamine producers that may worsen symptoms.

“Lactobacillus GG,” in contrast, is unambiguous. The “GG” designation refers to a single, patented, well-characterized organism: Lacticaseibacillus rhamnosus GG, ATCC 53103 (formerly Lactobacillus rhamnosus GG, abbreviated LGG®). Originally isolated from a healthy human stool sample by Sherwood Gorbach and Barry Goldin in 1985, LGG is the single most studied probiotic strain in the world, with thousands of publications and an extensive safety dossier.

This article reviews what the published, peer-reviewed evidence actually says about LGG in the context of MCAS, histamine intolerance, and allergic disease — and where the evidence ends and clinical individualization begins.

Is LGG a Histamine-Producing Strain?

This is the first question that matters for any MCAS or histamine-intolerant patient. Histamine production by bacteria depends on whether the strain expresses functional histidine decarboxylase (HDC), the enzyme that converts the amino acid histidine into histamine.

In a 2021 in vitro study published in the Journal of Food Science and Technology, investigators directly assayed histamine and D-lactate production by Lacticaseibacillus rhamnosus GG (ATCC 53103) as one of the single-strain controls. Using enzymatic assays, no significant histamine production was detected compared to controls. This is consistent with the absence of a functional histidine decarboxylase in the LGG genome.

By comparison, well-documented histamine-producing probiotic species include certain strains of Lactobacillus reuteri, Lactobacillus casei, Lactobacillus bulgaricus, Streptococcus thermophilus, and several wild Lactobacillus strains used in fermented foods. These are categorically different from LGG and should not be conflated with it.

Practical clinical takeaway: On the histamine-production axis, LGG behaves as a low-histamine, histamine-neutral organism. This is the foundation that makes the rest of the evidence relevant.

Direct Mast-Cell Evidence: What LGG Actually Does to Mast Cells

Beyond simply not producing histamine, LGG has been shown in two independent and methodologically distinct studies to actively modulate mast-cell behavior in directions that are clinically relevant for MCAS.

Human Mast-Cell Gene Expression (Oksaharju et al., 2011)

In a study published in the World Journal of Gastroenterology, investigators stimulated human peripheral-blood-derived mast cells with four probiotic organisms — LGG, L. rhamnosus Lc705, Propionibacterium freudenreichii JS, and Bifidobacterium animalis Bb12 — and performed global microarray gene-expression analysis using the Affymetrix Human Genome U133 Plus 2.0 Array.

The findings were striking and strain-specific. Both L. rhamnosus strains — LGG and Lc705 — but neither the propionibacterium nor the bifidobacterium, suppressed expression of:

• FCER1A and FCER1G — the alpha and gamma subunits of the high-affinity IgE receptor (FcεRI), the central trigger of IgE-mediated mast-cell degranulation, and
• HRH4 — the histamine H4 receptor, expressed on mast cells themselves and involved in autocrine amplification of mast-cell activation and chemotaxis.

Translated into clinical language, exposure to LGG genetically dialed down two of the most important molecular triggers of mast-cell activation. This is mechanistic data, not symptom data — but it is data that runs in the right direction for an MCAS patient.

Functional Mast-Cell Stabilization (Forsythe et al., 2012)

A subsequent study published in PLoS ONE examined the systemic functional consequences of orally ingested L. rhamnosus (strain JB-1) in rats. After nine days of oral feeding, peritoneal mast cells were harvested and patch-clamp studies were performed.

The treated animals showed significant inhibition of mast-cell mediator release across multiple stimuli, including IgE-mediated activation. Passive cutaneous anaphylaxis responses were also reduced. Mechanistically, the effect was traced to suppression of the calcium-activated potassium channel KCa3.1, a critical regulator of mast-cell degranulation.

Although JB-1 and GG are different L. rhamnosus strains, the convergent finding — that L. rhamnosus strains can systemically stabilize mast cells through more than one molecular mechanism — strengthens the biological plausibility of using LGG specifically in MCAS.

Gut Barrier: An Underappreciated MCAS Mechanism

MCAS does not exist in isolation. In clinical practice, the overlap with intestinal permeability (“leaky gut”), food sensitivities, post-infectious gastrointestinal dysfunction, and bile-acid dysregulation is striking. A weakened gut barrier increases antigenic load, which in turn increases mast-cell activation in the gut wall and beyond.

LGG has one of the most robust gut-barrier evidence bases of any probiotic. In Caco-2 epithelial cell systems, LGG — viable, heat-inactivated, and as conditioned medium — has been shown to preserve transepithelial electrical resistance (TEER) and protect tight-junction protein expression (ZO-1, claudin-1, occludin) against gliadin-induced disruption. In vivo studies in Wistar rats demonstrate that LGG protects the intestinal mucosa against pepsin-trypsin-digested gliadin enteropathy by preserving expression of the same tight-junction and adherens-junction proteins.

More recent work on heat-inactivated LGG (postbiotic) in cow’s milk allergy has shown beneficial modulation of regulatory T-cell activation, cytokine balance, mucin-2 expression, lactase expression, and FITC-dextran permeability — a panel that essentially describes restored barrier integrity.

For MCAS patients, the relevance is direct: less paracellular leak means less luminal antigen reaching mucosal mast cells, which means a lower baseline activation state.

Allergic Disease: The Adjacent Clinical Evidence

MCAS is not classical IgE-mediated allergy, but the two domains share enough biology that allergic-disease trial data is informative.

The strongest body of LGG clinical evidence is in pediatric cow’s milk allergy (CMA). Across more than 2,200 pediatric CMA patients in multiple randomized trials, LGG — alone or combined with extensively hydrolyzed casein formula — accelerated acquisition of immune tolerance and reduced the occurrence of subsequent allergic manifestations (the so-called “allergic march”), with effects sustained at three-year follow-up.

In atopic dermatitis (AD), LGG has been studied in randomized trials in infants with AD, where it modulates skin and gut microbiota and humoral immune responses. Pediatric network meta-analyses of probiotic strains for AD prevention rank LGG among the better-studied options, although effect sizes are modest and outcomes vary by population.

None of these are MCAS trials. They are, however, real human clinical data showing that LGG has measurable, reproducible effects on the same allergic and immune-tolerance pathways that are dysregulated in MCAS.

Safety Profile and Real-World Cautions

LGG has been studied in Phase I safety trials at doses up to 1×10¹⁰ CFU twice daily for six months in healthy adults, and at similar doses for shorter durations in elderly subjects. The strain has been consumed by tens of millions of people worldwide for decades, and large epidemiologic surveillance has documented an extremely low rate of bacteremia, almost exclusively confined to severely immunocompromised patients, those with central venous catheters, or those with significant gut barrier breach (e.g., short bowel syndrome, severe acute pancreatitis).

Standard contraindications and cautions include:

• Severe immunosuppression (e.g., active chemotherapy with neutropenia, post-transplant on heavy immunosuppressants, advanced HIV)
• Indwelling central venous catheters or recent major cardiovascular surgery with prosthetic valves
• Critical illness with significant gut barrier compromise (e.g., severe acute pancreatitis — historical signal for harm)
• Short bowel syndrome or other states with high baseline translocation risk

MCAS-specific caution: Even with a histamine-neutral, mast-cell-modulating organism like LGG, mast-cell-sensitive patients can react paradoxically to any new oral input. The clinically prudent approach is a low starting dose (often a fraction of a capsule, opened and divided), advancement only after tolerance is established, and discontinuation if symptoms worsen rather than improve over a defined trial period.

Where LGG Fits in an Integrative MCAS Protocol

LGG is not a stand-alone MCAS treatment, and no probiotic should be presented as one. In my integrative practice at www.directintegrativecare.com, I think of LGG as one of several foundation-layer interventions that can be considered after the obvious mast-cell triggers — dietary histamine load, environmental mold, infections, hormonal triggers — have been addressed.

The decision to trial LGG in a given MCAS patient typically rests on a few clinical features:

• Predominant gut-mediated symptoms (post-prandial flushing, bloating, abdominal pain, food reactivity)
• Documented or suspected intestinal hyperpermeability on functional testing
• Prior history of recurrent antibiotic exposure or post-infectious GI dysfunction
• Concurrent atopic disease, food allergy, or family history of allergic march

LGG is generally combined with mast-cell stabilization (H1 and H2 antagonists, quercetin, luteolin), targeted micronutrient repletion, dietary histamine modulation, and — where appropriate — Low Dose Naltrexone for its independent immunomodulatory effects. This multi-axis approach is the standard of care in integrative MCAS practice and is consistent with how LGG was used in the published MCAS case literature.

Practical Takeaway

If a patient or clinician asks me whether “Lactobacillus GG” is appropriate in MCAS, the short answer is: 

• Yes, it is the strain most defensible from a histamine-production standpoint — it does not produce histamine in standard assays.
• Yes, it has direct mechanistic evidence of mast-cell receptor downregulation — specifically FcεRI and HRH4.
• Yes, it has the strongest gut-barrier evidence of any single probiotic strain, which matters because gut barrier is part of the MCAS feedback loop.
• And yet  — because MCAS is unpredictable — individual patient response remains the final arbiter, and probiotic introduction in MCAS should always be slow, monitored, and integrated into a broader plan.

If you are evaluating a probiotic and the label says only “LL” or “Lactobacillus,” that is not enough information to make this judgment. The exact species and strain code (e.g., ATCC 53103 for LGG) is what determines whether the published evidence applies. When in doubt, request the full strain identifier from the manufacturer before recommending or consuming the product.

References

All references below are peer-reviewed publications indexed in PubMed or PubMed Central. Hyperlinks point to the corresponding NCBI record.

1. Oksaharju A, Kankainen M, Kekkonen RA, et al. Probiotic Lactobacillus rhamnosus downregulates FCER1 and HRH4 expression in human mast cells. World J Gastroenterol. 2011;17(6):750-759. [PubMed/PMC]

2. Forsythe P, Wang B, Khambati I, Kunze WA. Systemic effects of ingested Lactobacillus rhamnosus: inhibition of mast cell membrane potassium (IKCa) current and degranulation. PLoS One. 2012;7(7):e41234. [PubMed/PMC]

3. Paparo L, Coppola S, Nocerino R, et al. Postbiotic effects elicited by heat-inactivated Lacticaseibacillus rhamnosus GG against cow's milk allergy in human cells. Front Immunol. 2024. [PubMed/PMC]

4. Nermes M, Kantele JM, Atosuo TJ, Salminen S, Isolauri E. Interaction of orally administered Lactobacillus rhamnosus GG with skin and gut microbiota and humoral immunity in infants with atopic dermatitis. Clin Exp Allergy. 2011;41(3):370-377. [PubMed/PMC]

5. Orlando A, Linsalata M, Notarnicola M, Tutino V, Russo F. Lactobacillus GG restoration of the gliadin induced epithelial barrier disruption: the role of cellular polyamines. BMC Microbiol. 2014;14:19. [PubMed/PMC]

6. Orlando A, Linsalata M, Bianco G, et al. Lactobacillus rhamnosus GG protects the epithelial barrier of Wistar rats from the pepsin-trypsin-digested gliadin (PTG)-induced enteropathy. Nutrients. 2018;10(11):1698. [PubMed/PMC]

7. Tan-Lim CSC, Esteban-Ipac NAR, Recto MST, Castor MAR, Casis-Hao RJ, Nano ALM. Comparative effectiveness of probiotic strains on the prevention of pediatric atopic dermatitis: a systematic review and network meta-analysis. Pediatr Allergy Immunol. 2021;32(6):1255-1270. [PubMed/PMC]

8. Berni Canani R, Di Costanzo M, Bedogni G, et al. Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG reduces the occurrence of other allergic manifestations in children with cow's milk allergy: 3-year randomized controlled trial. J Allergy Clin Immunol. 2017;139(6):1906-1913. [PubMed/PMC]

9. Mahdy MS, Azmy AF, Dishisha T, et al. Irritable bowel syndrome: evidence-based therapeutic role of probiotics, particularly Lactobacillus rhamnosus GG. Appl Microbiol Biotechnol. 2022;106(12):4445-4459. [PubMed/PMC]

10. Capurso L. Thirty years of Lactobacillus rhamnosus GG: a review. J Clin Gastroenterol. 2019;53 Suppl 1:S1-S41. [PubMed/PMC]

11. Vanderhoof JA, Young R. Probiotics in the United States. Clin Infect Dis. 2008;46 Suppl 2:S67-S72. [PubMed/PMC]

12. Castellanos Tapia A, Beed A, Castor C, et al. Complex presentations, identification and treatment of Mast Cell Activation Syndrome and associated conditions: a case report. Integr Med (Encinitas). 2023;22(4):28-37. [PubMed/PMC]